Tolerability and Treatment Compliance with Angiotensin II Receptor Antagonists

American Journal of Hypertension

Volumn 16, Issue 12, 2003, Pages 1066-1073

  Mancia, Giuseppe ^a,b,c,d   Seravalle, Gino ^c   Grassi, Guido ^a,b,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Ctro Interuniversitario Fisiol C   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

Author keywords

Angiotensin II antagonists; Antihypertensive drug treatment; Blood pressure control; Compliance; Systolic blood pressure; Tolerability

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

EID: 0345490819     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.07.012     Document Type: Review

References (62)

1. Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB: Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996;93:697-703.
2. Murray CJI, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Geneva: World Health Organization, 1996:1-158.
3. Blood Pressure Lowering Treatment Trialists' Collaboration: Effect of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000;356:1955-1964.
4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.
5. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
6. The Sixth report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.
7. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D: Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-1331.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeld D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.
9. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.
10. PROGRESS Collaborative Group: Randomized trial of perindopril-based pressure lowering regimen among 6125 patients with prior stroke or transient ischemic attack. Lancet 2001;358:1033-1041.
11. HOPE Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
12. Estacio RO, Jeffers B, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
13. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ: Trends in prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26:60-69.
14. Mancia G, Seravalle G, Grassi G: Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002; 20(suppl5):S21-S28.
15. Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, Sega R: Systolic versus diastolic blood pressure control in hypertensive patients of the PAMELA population. Arch Intern Med 2002;162:582-586.
16. Erdine S: How well is hypertension controlled in Europe? J Hypertens 2000;18:1348-1349.
17. Chockalingham A, Fodor JG: Treatment of raised blood pressure in the population: the Canadian experience. Am J Hypertens 1998;11: 747-749.
18. Coca A: Actual blood pressure control: are we doing things right? J Hypertens 1998;16(suppl 1):S45-S51.
19. Marques-Vidal P, Tuomilheto J: Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid ? J Hum Hypertens 1997;11:213-220.
20. Jamrozik K, Hockey R: Trends in risk factors for vascular disease in Australia. Med J Australia 1989;150:14-18.
21. Hozawa A, Ohkubo T, Kikuya M, Yamaguchi J, Ohmori K, Fujiwara T, Hashimoto J, Matsubar M, Kitaoka H, Nagai K, Tsuji I, Satoh H, Hisamichi S, Imai Y: Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 2002;25:57-63.
22. Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L: Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002;162:577-581.
23. Ambrosioni E: Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001;14(suppl 3):S33-S40.
24. Messerli FH, Grossman E, Goldbourt U: Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens 2001;14:12S-16S.
25. EUROASPIRE Study Group: A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997;18:1568-1582.
26. EUROASPIRE Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
27. Mancia G: Clinical benefits of consistent reduction in the daily blood pressure of hypertensive patients. J Clin Hypertens 2002; 4(suppl 1):9-14.
28. Lamb RE, Bradford MJ: Controlling hypertension to reduce the risk of stroke. Prog Cardiovasc Nurs 2002;17:186-191.
29. Waeber B, Burnier M, Brunner HR: The problem of compliance with antihypertensive therapy, in Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrari A, Wilkinson I (eds): Manual of Hypertension. London, Churchill Livingstone, 2002, pp 499-518.
30. Mallion JM, Schmitt D: Patient compliance in the treatment of arterial hypertension. J Hypertens 2001;19:2281-2283.
31. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP: Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 1995;11:293-295.
32. Caro JJ: Stepped care for hypertension: are the assumptions valid? J Hypertens 1997;15(Suppl):S35-S39.
33. Rizzo JA, Simons WR: Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-1457.
34. Alderman MH: Barriers to blood pressure control. Am J Hypertens 1999;2:1268-1269.
35. Samson-Fisher RW, Clover K: Compliance in the treatment of hypertension: a need for action. Am J Hypertens 1995;8:S82-S88.
36. Urquhart J: Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 1996; 17(suppl A):8-15.
37. Hansson L: Why don't you do as I tell you? Compliance and antihypertensive regimens. Int J Clin Pract 2002;56:191-196.
38. Sica DA: Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-462.
39. Dusing R: Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001;3:488-492.
40. Mancia G, Omboni S, Grassi G: Combination treatment in hypertension. Am J Hypertens 1997;10:1583-1585.
41. Mancia G: Improving the management of hypertension in clinical practice. J Hum Hypertens 1995;9(suppl 2):S29-S31.
42. Hughues D, McGuire A: The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998;12:533-537.
43. Mancia G, Grassi G: Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002;20:1461-1464.
44. Pitt B: Effects of angiotensin II antagonists in comparison to ACE inhibitors in patients with heart failure due to systolic left ventricular dysfunction. Heart Fail Rev 1999;3:221-232.
45. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristainsson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
46. Schiffrin EL, Park JB, Intengan HD, Touyz RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659.
47. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A: Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20:2293-2300.
48. Wachtell K, Dahlof B, Rokkedal J, Papademetriou V, Nieminen MS, Smith G, Gerdts E, Boman K, Bella JN, Devereux RB: Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002;144:1057-1064.
49. Mutlu H, Ozhan H, Okcun B, Okuyan E, Yigit Z, Erbas C, Kulukoglu MS, Gultekin N, Uner S, Erdine S, Guven O: The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy. Blood Press 2002;11:53-55.
50. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
51. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RL, Rhode R, Raz J: Renoprotective effects of the angiotensin-receptor antagonists irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
52. Parving HH, Lehnert H, Brockner-Mortesen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
53. Viberti G, Wheeldon NM: Microalbuminuria reduction in patients with type 2 diabetes mellitus: a blood-independent effect. Circulation 2002;106:672-678.
54. Lindholm LH, Ibsen H, Dahlof B, Deverux RB, Beevers G, Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomised trial against atenolol. Lancet 2002;359:1004-1010.
55. Goldberg AL, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium and angiotensin II receptor antagonist compared with hydrochlorothiazide, atenolol, felodipine ER and angiotensin-converting-enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-795.
56. Weber M: Clinical safety and tolerability of losartan. Clin Ther 1997;19:604-616.
57. Mazzolai L, Burnier M: Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Safety 1999;1:23-33.
58. Mann RD, Mackay F, Pearce G, Freemantle S, Wilton L: Losartan: a study of pharmacovigilance data on 14552 patients. J Human Hypertens 1999;13:551-557.
59. Gregoire JP, Moisan J, Guibert R, Ciampi A, Milot A, Cote I, Gaudet M: Tolerability of antihypertensive drugs in a community-based setting. Clin Ther 2001;23:715-726.
60. Bloom BS: Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-681.
61. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ: Four-year persistence pattern among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999-2010.
62. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.